Development and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line

Santin, Alessandro D.; Ioli, Gene R.; Hiserodt, John C.; Rose, G. Scott; Gräf, Martin; Tocco, Lisa M.; Lander, Jeffrey K.; Eck, Lawrence M.; Burger, Robert A.; DiSaia, Philip J.; Pecorelli, Sërgio; Granger, Gale A.

doi:10.1006/gyno.1995.1216

Cited by 19 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The UCI101luc cell line was chosen over the other cell lines for the SCID mouse model because it overexpresses both Her2 receptor and CA125 antigen, which allowed us to test both BSAbxCA125 and BSAbxHer2. Furthermore, the UCI-101luc cell line has undergone extensive cytologic and histologic evaluation using xenograft model (24,25). The UCI-101 carcinomatosis model using tumor xenografts was initially described in 1993 (26).…”

mentioning

confidence: 99%

Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study

Chan¹,

Hamilton²,

Cheung³

et al. 2006

Clinical Cancer Research

112

View full text Add to dashboard Cite

Cr release assay of fresh ovarian cancer cells exposed to autologous CIK cells increased from 21.7 F 0.3% to 89.4 F 2.1% at an E:Tratio of100:1 (P < 0.001). Anti-NKG2D antibodies attenuated the CIK activity by 56.8% on primary cells (P < 0.001). In a xenograft severe combined immunodeficient mouse model, real-time tumor regression and progression was visualized using a noninvasive in vivo bioluminescence imaging system. Four hours after CIK cell injection, we were able to visualize CD8 + NKG2D + CIK cells infiltrating Her2-expressing cancer cells on fluorescence microscopy. Mice that underwent adoptive transfer of CIK cells redirected with BSAbxCA125 and BSAbxHer2 had significant reduction in tumor burden (P < 0.001and P < 0.001) and improvement in survival (P = 0.05 and P = 0.006) versus those treated with CIK cells alone. Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor.

show abstract

mentioning

confidence: 99%

Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study

Chan¹,

Hamilton²,

Cheung³

et al. 2006

Clinical Cancer Research

112

View full text Add to dashboard Cite

show abstract

“…Based on the biological rationale of increasing the immunogenicity of ovarian cancer cells by transfer of an immunostimulatory cytokine gene, Santin et al . have developed an IL‐4 secreting human ovarian carcinoma cell line using retroviral‐mediated gene transduction ( 47 , 48 ) . The cell line termed UCI107E was shown to express IL‐4 between 900–1300 pg ml −1 per 10 5 cells in 48 h. Characterization of this cell line revealed expression of MHC I and HER‐2/neu surface antigens.…”

Section: Immuno‐gene Therapymentioning

confidence: 99%

Gene therapy for ovarian cancer: development of novel treatment strategies

Dorigo¹,

Berek²

1997

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Briefly, single cell suspensions were obtained by processing solid tumor samples under sterile conditions at room temperature. Viable tumor tissue was mechanically minced in RPMI 1640 to portions no larger than 1±3 mm 3 and washed twice with RPMI 1640. The portions of minced tumor were then placed into 250 ml trypsinizing flasks containing 30 ml of enzyme solution [0.14% Collagenase Type I (Sigma) and 0.01% DNAse (Sigma, 2000 KU mg 71 )] in RPMI 1640, and incubated on a magnetic stirring apparatus overnight at 48C.…”

Section: Tumor Cell Linesmentioning

confidence: 99%

“…We have recently developed and characterized human ovarian carcinoma tumor vaccines secreting different cytokines to be used as vaccines for women with advanced ovarian cancer ( 3 –5 ) . We have proposed that such cytokine secreting vaccines will be mixed with irradiated autologous tumor cells obtained at the time of surgical debulking.…”

mentioning

confidence: 99%

Expression and cytokine mediated modulation of adhesion/costimulation molecules ICAM-1(CD54) and LFA-3(CD58) in human ovarian cancer

Santin

Hermonat

Hiserodt

et al. 1997

Int J Gynecol Cancer

View full text Add to dashboard Cite

Previous studies have shown that paracrine delivery of helper cytokines by transduced tumor cells can bypass the lack of the B7 costimulation pathway, which when engaged induces secretion of a number of cytokines, most notably IL‐2 and which results in clonal T‐cell proliferation and effector function. However, other costimulation signals such as those mediated by ICAM‐1 and LFA‐3 molecules remain crucial to increase antigen independent conjugate formation and therefore synergize with TcR activation pathways. In this study we have analyzed tumor cells from eight freshly isolated and histologically similar human ovarian tumors for their surface antigen expression of the adhesion/costimulation molecules ICAM‐1 and LFA‐3 before and after exposure to the cytokines TNF‐α plus IFN‐γ. All eight fresh tumors expressed variable levels of ICAM‐1 antigens and these levels were markedly upregulated after exposure to TNF‐α plus IFN‐γ. Similarly, LFA‐3 antigens were shown to be expressed in all fresh tumor evaluated. However, in contrast to the ICAM‐1/LFA‐1 pathway of costimulatory molecules, LFA‐3/CD2 pathway was shown to be resistant to modulation with these cytokines. Such findings suggest that fresh ovarian tumor cells pretreated with TNF‐α plus IFN‐γ could significantly increase their adhesion/costimulation activity for T cell recognition when admixed with genetically manipulated tumor cells to be used as tumor vaccines.

show abstract

Development and Characterization of an IL-4-Secreting Human Ovarian Carcinoma Cell Line

Cited by 19 publications

References 0 publications

Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study

Enhanced Killing of Primary Ovarian Cancer by Retargeting Autologous Cytokine-Induced Killer Cells with Bispecific Antibodies: A Preclinical Study

Gene therapy for ovarian cancer: development of novel treatment strategies

Expression and cytokine mediated modulation of adhesion/costimulation molecules ICAM-1(CD54) and LFA-3(CD58) in human ovarian cancer

Contact Info

Product

Resources

About